<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35367591</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1464-3405</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>67</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Bioorganic &amp; medicinal chemistry letters</Title>
          <ISOAbbreviation>Bioorg Med Chem Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>6-Aryl-quinazolines as novel GABA<sub>B</sub> receptor positive allosteric modulators.</ArticleTitle>
        <Pagination>
          <StartPage>128714</StartPage>
          <MedlinePgn>128714</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2022.128714</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0960-894X(22)00190-1</ELocationID>
        <Abstract>
          <AbstractText>The systemic use of GABA<sub>B</sub> orthosteric agonist baclofen might be limited due to its detrimental properties: sedation and motor impairment. In contrast, GABA<sub>B</sub> positive allosteric modulators produce less adverse effects. Using BHF-177 as a starting point, we found a new active scaffold: the 6-aryl-quinazoline scaffold. Further elaborating the scaffold, we identified several in vitro and in vivo active compounds.</AbstractText>
          <CopyrightInformation>Copyright © 2022. Published by Elsevier Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huszár</LastName>
            <ForeName>József</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary. Electronic address: jo.huszar@richter.hu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petró</LastName>
            <ForeName>József Levente</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hadady</LastName>
            <ForeName>Zsuzsa</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bobok</LastName>
            <ForeName>Amrita Ágnes</ForeName>
            <Initials>AÁ</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sághy</LastName>
            <ForeName>Katalin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Halász</LastName>
            <ForeName>Attila Sándor</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hornyánszky</LastName>
            <ForeName>Gábor</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, 8 Budafoki Street, Budapest H-1111, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Román</LastName>
            <ForeName>Viktor</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Greiner</LastName>
            <ForeName>István</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Éles</LastName>
            <ForeName>János</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Works of Gedeon Richter Plc, 30-32 Gyömrői Street, Budapest H-1103, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Bioorg Med Chem Lett</MedlineTA>
        <NlmUniqueID>9107377</NlmUniqueID>
        <ISSNLinking>0960-894X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058786">GABA-B Receptor Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018080">Receptors, GABA-B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H789N3FKE8</RegistryNumber>
          <NameOfSubstance UI="D001418">Baclofen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001418" MajorTopicYN="N">Baclofen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058786" MajorTopicYN="Y">GABA-B Receptor Agonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018080" MajorTopicYN="Y">Receptors, GABA-B</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">GABA</Keyword>
        <Keyword MajorTopicYN="Y">GABA(B) receptor</Keyword>
        <Keyword MajorTopicYN="Y">PAMs</Keyword>
        <Keyword MajorTopicYN="Y">Positive allosteric modulators</Keyword>
        <Keyword MajorTopicYN="Y">γ-Aminobutyric acid</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>20</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35367591</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bmcl.2022.128714</ArticleId>
        <ArticleId IdType="pii">S0960-894X(22)00190-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
